158 related articles for article (PubMed ID: 25477282)
1. A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation.
Hijmans BS; Tiemann CA; Grefhorst A; Boesjes M; van Dijk TH; Tietge UJ; Kuipers F; van Riel NA; Groen AK; Oosterveer MH
FASEB J; 2015 Apr; 29(4):1153-64. PubMed ID: 25477282
[TBL] [Abstract][Full Text] [Related]
2. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
[TBL] [Abstract][Full Text] [Related]
3. Reduced insulin-mediated inhibition of VLDL secretion upon pharmacological activation of the liver X receptor in mice.
Grefhorst A; Parks EJ
J Lipid Res; 2009 Jul; 50(7):1374-83. PubMed ID: 19287042
[TBL] [Abstract][Full Text] [Related]
4. Fetal liver X receptor activation acutely induces lipogenesis but does not affect plasma lipid response to a high-fat diet in adult mice.
van Straten EM; van Meer H; Huijkman NC; van Dijk TH; Baller JF; Verkade HJ; Kuipers F; Plösch T
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1171-8. PubMed ID: 19724022
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
[TBL] [Abstract][Full Text] [Related]
6. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice.
Jung UJ; Millman PN; Tall AR; Deckelbaum RJ
Biochim Biophys Acta; 2011 Sep; 1811(9):491-7. PubMed ID: 21704188
[TBL] [Abstract][Full Text] [Related]
7. Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
Gao M; Bu L; Ma Y; Liu D
PLoS One; 2013; 8(6):e65641. PubMed ID: 23762402
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.
Grefhorst A; Elzinga BM; Voshol PJ; Plösch T; Kok T; Bloks VW; van der Sluijs FH; Havekes LM; Romijn JA; Verkade HJ; Kuipers F
J Biol Chem; 2002 Sep; 277(37):34182-90. PubMed ID: 12097330
[TBL] [Abstract][Full Text] [Related]
9. Parameter trajectory analysis to identify treatment effects of pharmacological interventions.
Tiemann CA; Vanlier J; Oosterveer MH; Groen AK; Hilbers PA; van Riel NA
PLoS Comput Biol; 2013; 9(8):e1003166. PubMed ID: 23935478
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of gomisin N against hepatic steatosis through AMPK activation.
Yun YR; Kim JH; Kim JH; Jung MH
Biochem Biophys Res Commun; 2017 Jan; 482(4):1095-1101. PubMed ID: 27914812
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice.
Gao M; Liu D
AAPS J; 2013 Jul; 15(3):744-52. PubMed ID: 23591747
[TBL] [Abstract][Full Text] [Related]
14. Liver X receptor
Heckmann BL; Zhang X; Saarinen AM; Schoiswohl G; Kershaw EE; Zechner R; Liu J
JCI Insight; 2017 Feb; 2(4):e88735. PubMed ID: 28239648
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Srivastava RA
Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
[TBL] [Abstract][Full Text] [Related]
16. CCAAT/enhancer binding protein β deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis.
Rahman SM; Choudhury M; Janssen RC; Baquero KC; Miyazaki M; Friedman JE
Biochem Biophys Res Commun; 2013 Jan; 430(1):336-9. PubMed ID: 23159614
[TBL] [Abstract][Full Text] [Related]
17. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.
Zhou J; Febbraio M; Wada T; Zhai Y; Kuruba R; He J; Lee JH; Khadem S; Ren S; Li S; Silverstein RL; Xie W
Gastroenterology; 2008 Feb; 134(2):556-67. PubMed ID: 18242221
[TBL] [Abstract][Full Text] [Related]
18. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice.
Wu J; Wang C; Li S; Li S; Wang W; Li J; Chi Y; Yang H; Kong X; Zhou Y; Dong C; Wang F; Xu G; Yang J; Gustafsson JÅ; Guan Y
Hepatology; 2013 Aug; 58(2):617-28. PubMed ID: 23348573
[TBL] [Abstract][Full Text] [Related]
19. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice.
Zhang Y; Breevoort SR; Angdisen J; Fu M; Schmidt DR; Holmstrom SR; Kliewer SA; Mangelsdorf DJ; Schulman IG
J Clin Invest; 2012 May; 122(5):1688-99. PubMed ID: 22484817
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
